Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Proteon Therapeutics, Inc is an other business based in the US. Proteon Therapeutics shares (PRTO) are listed on the NASDAQ and all prices are listed in US Dollars. Proteon Therapeutics employs 17 staff and has a market cap (total outstanding shares value) of USD$18.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
52-week range | USD$0.11 - USD$0.435 |
---|---|
50-day moving average | USD$0.835 |
200-day moving average | USD$1.7147 |
Wall St. target price | USD$1 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.139 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -63.42% |
Return on equity TTM | -113.3% |
Profit margin | 0% |
Book value | $-0.598 |
Market capitalisation | USD$18.5 million |
TTM: trailing 12 months
There are currently 123,371 Proteon Therapeutics shares held short by investors – that's known as Proteon Therapeutics's "short interest". This figure is 38.3% down from 199,813 last month.
There are a few different ways that this level of interest in shorting Proteon Therapeutics shares can be evaluated.
Proteon Therapeutics's "short interest ratio" (SIR) is the quantity of Proteon Therapeutics shares currently shorted divided by the average quantity of Proteon Therapeutics shares traded daily (recently around 152309.87654321). Proteon Therapeutics's SIR currently stands at 0.81. In other words for every 100,000 Proteon Therapeutics shares traded daily on the market, roughly 810 shares are currently held short.
However Proteon Therapeutics's short interest can also be evaluated against the total number of Proteon Therapeutics shares, or, against the total number of tradable Proteon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Proteon Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Proteon Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0114% of the tradable shares (for every 100,000 tradable Proteon Therapeutics shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Proteon Therapeutics.
Find out more about how you can short Proteon Therapeutics stock.
We're not expecting Proteon Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Proteon Therapeutics's shares have ranged in value from as little as $0.11 up to $0.435. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteon Therapeutics's is 0.6027. This would suggest that Proteon Therapeutics's shares are less volatile than average (for this exchange).
As of January 9, 2020, Proteon Therapeutics, Inc. was acquired by ArTara Therapeutics, Inc., in a reverse merger transaction. Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.